Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

These findings are consistent with the mechanism of action of spartalizumab and with data reported for inhibitors of PD-1 in other indications. 11 In summary, spartalizumab demonstrated promising ...

With its combined immune and antiangiogenic mechanisms, ivonescimab offers a promising new ... Phase III success in lung cancer and its second head-to-head win over a PD-1 inhibitor.1 Currently, the ...

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

HS1940 may broaden treatment options and improve outcomes across multiple types of cancer and may access receptor regions that other PD-1 inhibitors (e.g., nivolumab and pembrolizumab) may not reach.

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...